Tags : Discontinue

Halozyme to Discontinue its P-III HALO-301 Study of PEGPH20 for

Shots: Halozyme will discontinue its P-III HALO-301 study evaluating PEGPH20 in combination with gemcitabine and nab-paclitaxel (Abraxane) vs gemcitabine and nab-paclitaxel as a 1L therapy for the treatment of patients with metastatic pancreatic cancer The P-III HALO-301 study results: did not meet its 1EPs of OS (11.2 vs 11.5mos.) as there was a higher response […]Read More

Arbutus to Discontinue its P-Ia/Ib Clinical Study of AB-506 to

Shots: Arbutus discontinues its P-Ia/Ib study of AB-506 due to disappointing clinical findings i.e, observation of two cases of acute hepatitis in P-Ia clinical study assessing Ab-506 in healthy volunteers for 28days Following the results of P-Ia/Ib study, Abratus drop its plan to initiate combination study of AB-506 and AB-729 in H2’20 and will present […]Read More